Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

Exclusion Criteria

• •1. Damage to the optic nerve or spinal cord caused by other non-NMOSD-related factors.
• •2. Abnormal laboratory indicators that need to be excluded from the subjects include, but are not limited to the following indicators:
• •Neutrophils \< 1.5 × 109/L, Hemoglobin \< 90g/L, Platelet count \< 75 × 109/L; Serum creatinine \> 1.5 × ULN, Total bilirubin \> 1.5 × ULN, Aspartate aminotransferase (AST) \> 1.5 × ULN, Alanine aminotransferase (ALT) \> 1.5 × ULN, Alkaline phosphatase \> 2 × ULN ； HbA1c \> 8% (for diabetic patients); GFR \< 60 mL/minute/1.73m2.
• •3. Pregnant or lactating women, as well as those planning to become pregnant during the study period.
• •4. Those who have received PE/IA/IVIG/FcRn/B-cell deletion/C5/IL-6 treatment within 1 month before enrollment.
• •5. Active infections: active hepatitis B, hepatitis C, syphilis or HIV infection; active systemic infections or immunodeficiency diseases; unrelieved meningococcal infection of the meninges, or patients with severe infections that cannot use immunosuppressive drugs.
• •6. Patients with severe internal or external diseases (not limited to such as heart failure, unstable angina pectoris, respiratory failure, pulmonary insufficiency, cachexia, organ transplantation, etc.).
• •7. Those who have had or currently have an untreated malignant tumor that is not well controlled.
• •8. Patients with serious physical or mental diseases that may affect the smooth implementation of the study.
• •9. Patients known to be allergic to monoclonal drugs, murine proteins or any excipients.
• •10. Patients who are intolerant to methylprednisolone or gamma globulin.
• •11. Patients who cannot complete the magnetic resonance enhanced scan screening.
• •12. Patients who are participating in other interventional clinical trials.
• •13. Patients who cannot understand the questionnaire questions or cooperate with the questionnaire survey.
• •14. Situations that the research team collectively deems unsuitable for participation in this study.